vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Sprout Social, Inc. (SPT). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($196.9M vs $120.9M, roughly 1.6× Sprout Social, Inc.). On growth, Sprout Social, Inc. posted the faster year-over-year revenue change (12.9% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $9.9M). Over the past eight quarters, Sprout Social, Inc.'s revenue compounded faster (11.8% CAGR vs 8.5%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Sprout Social, Inc. is a technology company that runs a social media management platform. A public company headquartered in Chicago, it was founded in 2010 by Justyn Howard, Aaron Rankin, Gil Lara, and Peter Soung.
PCRX vs SPT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.9M | $120.9M |
| Net Profit | — | — |
| Gross Margin | 79.5% | 77.6% |
| Operating Margin | 1.2% | -9.0% |
| Net Margin | — | — |
| Revenue YoY | 5.1% | 12.9% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.05 | $-0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.9M | $120.9M | ||
| Q3 25 | $179.5M | $115.6M | ||
| Q2 25 | $181.1M | $111.8M | ||
| Q1 25 | $168.9M | $109.3M | ||
| Q4 24 | $187.3M | $107.1M | ||
| Q3 24 | $168.6M | $102.6M | ||
| Q2 24 | $178.0M | $99.4M | ||
| Q1 24 | $167.1M | $96.8M |
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $-9.4M | ||
| Q2 25 | $-4.8M | $-12.0M | ||
| Q1 25 | $4.8M | $-11.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | $-17.1M | ||
| Q2 24 | $18.9M | $-16.9M | ||
| Q1 24 | $9.0M | $-13.6M |
| Q4 25 | 79.5% | 77.6% | ||
| Q3 25 | 80.9% | 77.7% | ||
| Q2 25 | 77.4% | 77.7% | ||
| Q1 25 | 79.7% | 77.3% | ||
| Q4 24 | 78.7% | 78.1% | ||
| Q3 24 | 76.9% | 77.4% | ||
| Q2 24 | 75.1% | 77.5% | ||
| Q1 24 | 71.6% | 76.8% |
| Q4 25 | 1.2% | -9.0% | ||
| Q3 25 | 3.5% | -7.9% | ||
| Q2 25 | 4.7% | -11.0% | ||
| Q1 25 | 1.2% | -10.2% | ||
| Q4 24 | 13.2% | -12.8% | ||
| Q3 24 | -82.8% | -16.4% | ||
| Q2 24 | 15.9% | -16.6% | ||
| Q1 24 | 7.9% | -13.7% |
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | -8.1% | ||
| Q2 25 | -2.7% | -10.7% | ||
| Q1 25 | 2.8% | -10.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | -16.6% | ||
| Q2 24 | 10.6% | -17.0% | ||
| Q1 24 | 5.4% | -14.0% |
| Q4 25 | $0.05 | $-0.18 | ||
| Q3 25 | $0.12 | $-0.16 | ||
| Q2 25 | $-0.11 | $-0.21 | ||
| Q1 25 | $0.10 | $-0.19 | ||
| Q4 24 | $0.38 | $-0.25 | ||
| Q3 24 | $-3.11 | $-0.30 | ||
| Q2 24 | $0.39 | $-0.30 | ||
| Q1 24 | $0.19 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $238.4M | $95.3M |
| Total DebtLower is stronger | $372.2M | $40.0M |
| Stockholders' EquityBook value | $693.1M | $203.4M |
| Total Assets | $1.3B | $523.1M |
| Debt / EquityLower = less leverage | 0.54× | 0.20× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $238.4M | $95.3M | ||
| Q3 25 | $246.3M | $90.6M | ||
| Q2 25 | $445.9M | $101.5M | ||
| Q1 25 | $493.6M | $100.9M | ||
| Q4 24 | $484.6M | $86.4M | ||
| Q3 24 | $453.8M | $82.9M | ||
| Q2 24 | $404.2M | $80.9M | ||
| Q1 24 | $325.9M | $69.2M |
| Q4 25 | $372.2M | $40.0M | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | $25.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $693.1M | $203.4M | ||
| Q3 25 | $727.2M | $194.1M | ||
| Q2 25 | $757.8M | $184.6M | ||
| Q1 25 | $798.5M | $175.3M | ||
| Q4 24 | $778.3M | $166.6M | ||
| Q3 24 | $749.6M | $158.1M | ||
| Q2 24 | $879.3M | $152.1M | ||
| Q1 24 | $892.2M | $147.3M |
| Q4 25 | $1.3B | $523.1M | ||
| Q3 25 | $1.3B | $481.4M | ||
| Q2 25 | $1.5B | $422.9M | ||
| Q1 25 | $1.6B | $424.7M | ||
| Q4 24 | $1.6B | $428.3M | ||
| Q3 24 | $1.5B | $388.8M | ||
| Q2 24 | $1.6B | $393.6M | ||
| Q1 24 | $1.6B | $389.9M |
| Q4 25 | 0.54× | 0.20× | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | 0.15× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.7M | $10.9M |
| Free Cash FlowOCF − Capex | $43.5M | $9.9M |
| FCF MarginFCF / Revenue | 22.1% | 8.2% |
| Capex IntensityCapex / Revenue | 0.1% | 0.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $136.7M | $39.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $43.7M | $10.9M | ||
| Q3 25 | $60.8M | $9.3M | ||
| Q2 25 | $12.0M | $5.1M | ||
| Q1 25 | $35.5M | $18.1M | ||
| Q4 24 | $33.1M | $4.1M | ||
| Q3 24 | $53.9M | $9.0M | ||
| Q2 24 | $53.2M | $2.1M | ||
| Q1 24 | $49.1M | $11.2M |
| Q4 25 | $43.5M | $9.9M | ||
| Q3 25 | $57.0M | $8.5M | ||
| Q2 25 | $9.3M | $4.2M | ||
| Q1 25 | $26.9M | $16.7M | ||
| Q4 24 | $31.0M | $3.3M | ||
| Q3 24 | $49.8M | $8.5M | ||
| Q2 24 | $51.6M | $1.6M | ||
| Q1 24 | $46.3M | $10.1M |
| Q4 25 | 22.1% | 8.2% | ||
| Q3 25 | 31.7% | 7.4% | ||
| Q2 25 | 5.1% | 3.7% | ||
| Q1 25 | 15.9% | 15.3% | ||
| Q4 24 | 16.6% | 3.0% | ||
| Q3 24 | 29.6% | 8.3% | ||
| Q2 24 | 29.0% | 1.6% | ||
| Q1 24 | 27.7% | 10.4% |
| Q4 25 | 0.1% | 0.9% | ||
| Q3 25 | 2.2% | 0.7% | ||
| Q2 25 | 1.5% | 0.8% | ||
| Q1 25 | 5.1% | 1.2% | ||
| Q4 24 | 1.1% | 0.8% | ||
| Q3 24 | 2.4% | 0.5% | ||
| Q2 24 | 0.9% | 0.5% | ||
| Q1 24 | 1.7% | 1.1% |
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — | ||
| Q1 24 | 5.47× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
SPT
Segment breakdown not available.
